Safety of targeting tumor endothelial cell antigens

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Wagner, Samuel C ^a   Riordan, Neil H ^b   Ichim, Thomas E ^a   Szymanski, Julia ^a   Ma, Hong ^a   Perez, Jesus A ^c   Lopez, Javier ^c   Plata Munoz, Juan J ^d,e   Silva, Francisco ^f   Patel, Amit N ^f   Kesari, Santosh ^g  

^a Batu Biologics   (United States)

^b Medistem Panama   (Panama)

^c Pan Am Cancer Treatment Center   (Mexico)

^d SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^e Centre for Molecular and Cell Based Therapeutics   (Mexico)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g John Wayne Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CELL ANTIGEN; CIBG 247; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; ENDOGLIN; ENDOSIALIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GEMCITABINE; LISTERIOLYSIN O; NOTCH4 RECEPTOR; PLACENTAL ENDOTHELIAL CELL VACCINE; STEROID; SURVIVIN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; CANCER VACCINE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; AUTOIMMUNITY; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; COLON CARCINOMA; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; ENTEROCOLITIS; HUMAN; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; INTESTINE PERFORATION; LUNG CANCER; LUNG CARCINOMA; LUNG METASTASIS; MALIGNANT NEOPLASM; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; REVIEW; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR REJECTION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UVEITIS; VITILIGO; ADVERSE EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; VACCINATION; VASCULARIZATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; ENDOTHELIAL CELLS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; VACCINATION;

EID: 85007524675     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-0842-8     Document Type: Review

References (93)

1. HoptionCann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J. 2003;79(938):672-80.
2. Monjazeb AM, et al. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. J Immunotoxicol. 2012;9(3):248-58.
3. Chiang CL, Coukos G, Kandalaft LE. Whole tumor antigen vaccines: where are we? Vaccines (Basel). 2015;3(2):344-72.
4. Miska J, Devarajan P, Chen Z. The immunological identity of tumor: self implications. Oncoimmunology. 2013;2(4):e23794.
5. Gilboa E. The makings of a tumor rejection antigen. Immunity. 1999;11(3):263-70.
6. Gyorki DE, et al. The delicate balance of melanoma immunotherapy. Clin Transl Immunol. 2013;2(8):e5.
7. Dudley AC. Tumor endothelial cells. Cold Spring Harb Perspect Med. 2012;2(3):a006536.
8. Motz GT, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607-15.
9. Lund AW, et al. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep. 2012;1(3):191-9.
10. Gabrilovich DI, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096-103.
11. Folkman J. Fighting cancer by attacking its blood supply. Sci Am. 1996;275(3):150-4.
12. Pardoll DM. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA. 1999;96(10):5340-2.
13. Brain L, Wilkinson M. Subacute cerebellar degeneration associated with neoplasms. Brain. 1965;88(3):465-78.
14. Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol. 1983;14(6):609-13.
15. Greenlee JE, et al. Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: detection of Yo antigen in tumor tissue and fall in antibody titers following tumor removal. Ann Neurol. 1999;45(6):805-9.
16. Furneaux HM, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med. 1990;322(26):1844-51.
17. Greenlee JE, et al. Anti-Yo antibody uptake and interaction with its intracellular target antigen causes Purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers. PLoS One. 2015;10(4):e0123446.
18. Polans AS, et al. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA. 1995;92(20):9176-80.
19. Le Gal FA, et al. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol. 2001;117(6):1464-70.
20. Nordlund JJ, et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983;9(5):689-96.
21. Quaglino P, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol. 2010;21(2):409-14.
22. Coulie PG, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180(1):35-42.
23. Cox AL, et al. Identification of a peptide recognized by five melanomaspecific human cytotoxic T cell lines. Science. 1994;264(5159):716-9.
24. Kawakami Y, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 1994;91(14):6458-62.
25. Bakker AB, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179(3):1005-9.
26. Wang RF, et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996;184(6):2207-16.
27. Coulie PG, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA. 1995;92(17):7976-80.
28. Wolfel T, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995;269(5228):1281-4.
29. Robbins PF, et al. A mutated beta-catenin gene encodes a melanomaspecific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996;183(3):1185-92.
30. Topalian SL, et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med. 1996;183(5):1965-71.
31. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996;19(1):81-4.
32. Dudley ME, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-4.
33. Maker AV, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12(12):1005-16.
34. Robinson MR, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004;27(6):478-9.
35. Ku GY, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116(7):1767-75.
36. Beck KE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283-9.
37. Seaman S, et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007;11(6):539-54.
38. St Croix B, et al. Genes expressed in human tumor endothelium. Science. 2000;289(5482):1197-202.
39. Nanda A, et al. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res. 2004;64(3):817-20.
40. Hou J, Tian L, Wei Y. Cancer immunotherapy of targeting angiogenesis. Cell Mol Immunol. 2004;1(3):161-6.
41. Keenan BP, Jaffee EM. Whole cell vaccines-past progress and future strategies. Semin Oncol. 2012;39(3):276-86.
42. Sercarz EE, et al. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol. 1993;11:729-66.
43. Gammon G, Sercarz E. How some T cells escape tolerance induction. Nature. 1989;342(6246):183-5.
44. Drakesmith H, et al. In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. Proc Natl Acad Sci USA. 1998;95(25):14903-8.
45. Moudgil KD, Sercarz EE. Crypticity of self antigenic determinants is the cornerstone of a theory of autoimmunity. Discov Med. 2005;5(28):378-82.
46. Fischer E, et al. Cryptic epitopes induce high-titer humoral immune response in patients with cancer. J Immunol. 2010;185(5):3095-102.
47. Huang SP, et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci. 2004;11(4):517-27.
48. Wysocki PJ, et al. Gene-modified tumor vaccine secreting a designer cytokine hyper-interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Ther. 2010;17(7):465-75.
49. Lally KM, et al. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer. 2001;93(6):841-7.
50. Gavilondo JV, et al. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine. 2014;32(19):2241-50.
51. Miyazawa M, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010;101(2):433-9.
52. Khodarev NN, et al. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci. 2003;116(Pt 6):1013-22.
53. Bhati R, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol. 2008;172(5):1381-90.
54. Hellebrekers DM, et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 2006;66(22):10770-7.
55. Hellebrekers DM, et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 2007;67(9):4138-48.
56. Lokhov PG, Balashova EE. Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC). Hum Vaccin Immunother. 2015;11(3):689-98.
57. Harandi A. Immunoplacental therapy, a potential multi-epitope cancer vaccine. Med Hypotheses. 2006;66(6):1182-7.
58. Okaji Y, et al. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer. 2008;44(3):383-90.
59. Tanaka M, et al. Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma. Cancer Sci. 2013;104(2):200-5.
60. Ichim TE, et al. Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax. J Transl Med. 2015;13:90.
61. Plum SM, et al. Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction. Immunopharmacol Immunotoxicol. 2004;26(1):29-41.
62. Niethammer AG, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002;8(12):1369-75.
63. Seavey MM, et al. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu + breast tumors in a mouse model. J Immunol. 2009;182(9):5537-46.
64. Morera Y, et al. Immunogenicity and some safety features of a VEGFbased cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine. 2010;28(19):3453-61.
65. Jarosz M, et al. Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents. Gene Ther. 2013;20(3):262-73.
66. Xiang R, et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005;65(2):553-61.
67. Facciponte JG, et al. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest. 2014;124(4):1497-511.
68. Haller BK, et al. Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma. Oncogene. 2010;29(30):4276-86.
69. Fernandez Lorente A, et al. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax(R) EGF. World J Surg Oncol. 2013;11:275.
70. Zhang Z, et al. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010;17(3):499-512.
71. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871-82.
72. Chatterjee S, et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 2013;123(4):1732-40.
73. Basilio-de-Oliveira RP, Pannain VL. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors. World J Gastroenterol. 2015;21(22):6924-30.
74. Anderberg C, et al. Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med. 2013;210(3):563-79.
75. Jonker L, Arthur HM. Endoglin expression in early development is associated with vasculogenesis and angiogenesis. Mech Dev. 2002;110(1-2):193-6.
76. Torsney E, et al. Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation. 2003;107(12):1653-7.
77. Lebrin F, et al. Endoglin promotes endothelial cell proliferation and TGFbeta/ALK1 signal transduction. EMBO J. 2004;23(20):4018-28.
78. Jerkic M, et al. Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc Res. 2006;69(4):845-54.
79. Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta. 2012;1823(4):850-60.
80. Casanovas O, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8(4):299-309.
81. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116-29.
82. Fons P, et al. Tumor vasculature is regulated by FGF/FGFR signalingmediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs. J Cell Physiol. 2015;230(1):43-51.
83. Davis PJ, et al. Nanotetrac targets integrin alphavbeta3 on tumor cells to disorder cell defense pathways and block angiogenesis. Onco Targets Ther. 2014;7:1619-24.
84. Silva R, et al. Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol. 2008;28(10):1703-13.
85. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264(5158):569-71.
86. Brooks PC, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79(7):1157-64.
87. Hariharan S, et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007;18(8):1400-7.
88. MacFadyen JR, et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett. 2005;579(12):2569-75.
89. Christian S, et al. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. Am J Pathol. 2008;172(2):486-94.
90. Carson-Walter EB, et al. Characterization of TEM1/endosialin in human and murine brain tumors. BMC Cancer. 2009;9:417.
91. Brady J, et al. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol. 2004;63(12):1274-83.
92. Rouleau C, et al. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res. 2008;14(22):7223-36.
93. Bagley RG. Endosialin: from vascular target to biomarker for human sarcomas. Biomark Med. 2009;3(5):589-604.